The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 27876250 |
60 |
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH |
Jagiellonian University Medical College |
| 26988801 |
55 |
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents. |
Jagiellonian University Medical College |
| 26654202 |
99 |
Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex. |
Mayo Clinic |
| 25862198 |
52 |
Elimination of a cholecystokinin receptor agonist 'trigger' in an effort to develop positive allosteric modulators without intrinsic agonist activity. |
Mayo Clinic |
| 25769518 |
4 |
Development of a time-resolved fluorescence probe for evaluation of competitive binding to the cholecystokinin 2 receptor. |
University of Arizona |
| 8978852 |
10 |
Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent. |
Glaxo Wellcome Research and Development |
| 8558528 |
16 |
Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist"trigger". |
Glaxo Wellcome |
| 8709137 |
14 |
3-[2-(N-phenylacetamide)]-1,5-benzodiazepines: orally active, binding selective CCK-A agonists. |
Glaxo Wellcome Research and Development |
| 7650691 |
14 |
Modification of receptor selectivity and functional activity in cholecystokinin peptoid ligands. |
Glaxo Research Institute |
| 19815410 |
23 |
Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: tuning of receptor selectivity and in vivo efficacy. |
Johnson & Johnson Pharmaceutical Research and Development |
| 19811913 |
52 |
Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists I: discovery of CCKR1 selectivity in a previously CCKR2-selective lead series. |
Johnson & Johnson Pharmaceutical Research and Development |
| 19271701 |
4 |
Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors. |
Mayo Clinic |
| 17536796 |
106 |
Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion. |
James Black Foundation |
| 8709093 |
21 |
3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines: CCK-A agonists that demonstrate oral activity as satiety agents. |
Glaxo Wellcome Research and Development |
| 7837233 |
21 |
CCK-A receptor selective antagonists derived from the CCK-A receptor selective tetrapeptide agonist Boc-Trp-Lys(Tac)-Asp-MePhe-NH2 (A-71623). |
Glaxo Research Institute |
| 20684563 |
176 |
Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. |
H. Lundbeck |
| 20547453 |
122 |
Design and synthesis of trivalent ligands targeting opioid, cholecystokinin, and melanocortin receptors for the treatment of pain. |
University of Arizona |
| 16562853 |
22 |
Alkaloids from Eschscholzia californica and their capacity to inhibit binding of [3H]8-Hydroxy-2-(di-N-propylamino)tetralin to 5-HT1A receptors in Vitro. |
Tom'S of Maine |
| 16509592 |
101 |
Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. |
University of Arizona |
| 16220969 |
219 |
Designed multiple ligands. An emerging drug discovery paradigm. |
Organon Laboratories |
| 15456276 |
45 |
5-(tryptophylamino)-1,3-dioxoperhydropyrido[1,2-c]pyrimidine-based cholecystokinin receptor antagonists: reversal of CCK1 receptor subtype selectivity toward CCK2 receptors. |
Instituto De Qu£Mica M£Dica (Csic) |
| 13678399 |
54 |
Peptide science: exploring the use of chemical principles and interdisciplinary collaboration for understanding life processes. |
University of Arizona |
| 12477342 |
27 |
2002 Alfred Burger Award Address in Medicinal Chemistry. Natural products and design: interrelated approaches in drug discovery. |
Merck Research Laboratories |
| 9057851 |
30 |
Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor. |
University of Paris |
| 9397175 |
48 |
Synthesis and biological properties of new constrained CCK-B antagonists: discrimination of two affinity states of the CCK-B receptor on transfected CHO cells. |
University of Paris |
| 8831778 |
22 |
The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid recepto |
University of Arizona |
| 8568800 |
155 |
Structure-antigastrin activity relationships of new spiroglumide amido acid derivatives. |
Rotta Research Laboratorium |
| 8145219 |
20 |
High-affinity and potent, water-soluble 5-amino-1,4-benzodiazepine CCKB/gastrin receptor antagonists containing a cationic solubilizing group. |
Merck Sharp and Dohme Research Laboratories |
| 8126703 |
29 |
Tetrapeptide CCK-A agonists: effect of backbone N-methylations on in vitro and in vivo CCK activity. |
Abbott Laboratories |
| 7966139 |
6 |
Peptide-linked 1,3-dialkyl-3-acyltriazenes: gastrin receptor directed antineoplastic alkylating agents. |
National Cancer Institute-Frederick |
| 8295219 |
44 |
Tetrapeptide CCK agonists: structure-activity studies on modifications at the N-terminus. |
Abbott Laboratories |
| 8201591 |
2 |
CCK-A-selective tetrapeptides containing lys(N epsilon)-amide residues: favorable in vivo and in vitro effects of N-methylation at the aspartyl residue. |
Abbott Laboratories |
| 8277510 |
233 |
Development of 1,4-benzodiazepine cholecystokinin type B antagonists. |
Merck Research Laboratories |
| 8340909 |
14 |
Excursions in drug discovery. |
Merck Research Laboratories |
| 8421283 |
43 |
CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives. |
University of Paris |
| 1375964 |
112 |
Development of potent and selective CCK-A receptor agonists from Boc-CCK-4: tetrapeptides containing Lys(N epsilon)-amide residues. |
Abbott Laboratories |
| 1732532 |
139 |
Structure-antigastrin activity relationships of new (R)-4-benzamido-5-oxopentanoic acid derivatives. |
Rotta Research Laboratorium |
| 2299627 |
54 |
Novel glutamic acid derived cholecystokinin receptor ligands. |
Merck Sharp & Dohme Research Laboratories |
| 1700123 |
26 |
Development of CCK-tetrapeptide analogues as potent and selective CCK-A receptor agonists. |
Abbott Laboratories |
| 2909725 |
42 |
Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260. |
Merck Sharp & Dohme Research Laboratories |
| 2848124 |
401 |
Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. |
Merck Sharp & Dohme Research Laboratories |
| 2885419 |
179 |
Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists. |
TBA |
| | 32 |
Pseudopeptide CCK-4 analogues incorporating the [CH(CN)NH] peptide bond surrogate |
TBA |
| | 16 |
Conversion of acyclic nonpeptide CCK antagonists into CCK agonists |
Glaxo Wellcome Research and Development |
| | 10 |
Synthesis of novel iodinated radioligands with high affinity and selectivity for CCK-B/gastrin receptors |
TBA |
| | 7 |
Synthesis of a potent and selective non-peptide CCK-B/gastrin receptor antagonist tritiated ligand. |
TBA |
| | 27 |
Biological properties of (R)-4-benzamido-5-oxopentanoic basic derivatives as CCK-antagonists |
TBA |
| 21728335 |
20 |
New anthranilic acid based antagonists with high affinity and selectivity for the human cholecystokinin receptor 1 (hCCK1-R). |
University of Trieste |
| 21940174 |
4 |
A sucrose-derived scaffold for multimerization of bioactive peptides. |
The University of Arizona |
| 21456601 |
26 |
Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor. |
University Medical Centre Ljubljana |
| 21493064 |
69 |
Discovery of pyrimidine carboxamides as potent and selective CCK1 receptor agonists. |
Merck |
| 20813948 |
63 |
Spiroindolones, a potent compound class for the treatment of malaria. |
Swiss Tropical and Public Health Institute |
| | 28 |
Dual CCK-A and -B receptor antagonists (I) C9-methyl-1,4-benzodiazepines |
TBA |
| | 45 |
Synthesis and pharmacological evaluation of highly potent dual histamine H2 and gastrin receptor antagonists |
TBA |
| | 87 |
Design, synthesis, and pharmacological evaluation of dual histamine H2 and gastrin receptor antagonists |
TBA |
| | 66 |
Amino acid-derived piperidides as novel CCKB ligands with anxiolytic-like properties |
TBA |
| | 27 |
C5-piperazinyl-1,4-benzodiazepines, water-soluble, orally bioa vailable CCKB/gastrin receptor antagonists |
TBA |
| | 10 |
Potent, selective, water-soluble benzodiazepine-based CCKB receptor antagonists that contain lipophilic carboxylate surrogates |
TBA |
| | 42 |
A water soluble benzazepine cholecystokinin-B receptor antagonist |
TBA |
| | 6 |
CCKB selective receptor ligands: novel 1,3,5-trisubstituted benzazepin-2-ones |
TBA |
| | 58 |
5,7-Diphenyl-3-ureidohexahydroazepin-2-ones as Cholecystokinin-B receptor ligands |
TBA |
| | 24 |
Diphenylpyrazolidinone and benzodiazepine cholecystokinin antagonists: A case of convergent evolution in medicinal chemistry |
TBA |
| | 55 |
Benzolactams as non-peptide cholecystokinin receptor ligands |
TBA |
| | 54 |
Multipurpose receptor ligands: β-carboline cholecystokinin antagonists |
TBA |
| | 28 |
Toward developing peptidomimetics: Successful replacement of backbone amide bonds in tetrapeptide-based CCK-A receptor agonists |
TBA |
| | 18 |
On the significance of the C-terminal primary amide in cholecystokinin |
TBA |
| | 16 |
Structure-based design and pharmacological properties of potent selective and systemically active CCK-B peptidomimetics |
TBA |
| | 7 |
The design of a dipeptide library for screening at peptide receptor sites |
TBA |
| | 15 |
Tryptophan-norleucine 1,5-disubstituted tetrazoles as cis peptide bond mimics: Investigation of the bioactive conformation of a potent and selective peptide for the cholecystokinin-B receptor |
TBA |
| | 10 |
L-708,474: The C5-cyclohexyl analogue of L-365,260, a selective high affinity ligand for the CCKB/gastrin receptor |
TBA |
| | 17 |
1,3,4-trisubstituted pyrrolidinones as scaffolds for construction of peptidomimetic cholecystokinin antagonists |
TBA |
| 19113864 |
27 |
Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands. |
University of Minnesota |
| 18614364 |
109 |
Discovery of imidazole carboxamides as potent and selective CCK1R agonists. |
Merck Research Laboratories |
| 9722499 |
3 |
Recent natural products based drug development: a pharmaceutical industry perspective. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 17201419 |
93 |
Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. |
University of Arizona |
| 17034143 |
88 |
Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists. |
Johnson and Johnson Pharmaceutical Research and Development |
| 16033264 |
48 |
Combination of molecular modeling, site-directed mutagenesis, and SAR studies to delineate the binding site of pyridopyrimidine antagonists on the human CCK1 receptor. |
Instituto De QuíMica MéDica (Csic) |
| 11020275 |
75 |
Replacement of glycine with dicarbonyl and related moieties in analogues of the C-terminal pentapeptide of cholecystokinin: CCK(2) agonists displaying a novel binding mode. |
University of Paris |
| 30624060 |
224 |
Structure-Activity Relationships and Characterization of Highly Selective, Long-Acting, Peptide-Based Cholecystokinin 1 Receptor Agonists. |
TBA |
| 9873368 |
8 |
Relationship between dihedral angles of N1 and C9 substituents in 1,4-benzodiazepines and dual cholecystokinin-A and -B antagonistic activities. |
Fujisawa Pharmaceutical |
| 32150414 |
58 |
Bicyclic ?-Iminophosphonates as High Affinity Imidazoline I |
University of Barcelona |
| 32302139 |
11 |
Triazolo-Peptidomimetics: Novel Radiolabeled Minigastrin Analogs for Improved Tumor Targeting. |
Eth Zurich |
| 9544204 |
100 |
Novel nonpeptide CCK-B antagonists: design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists. |
Parke-Davis Pharmaceutical Research |
| 9397166 |
25 |
Class III antiarrhythmic activity in vivo by selective blockade of the slowly activating cardiac delayed rectifier potassium current IKs by (R)-2-(2,4-trifluoromethyl)-N-[2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)- 2, 3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide. |
Merck Research Laboratories |
| 9258356 |
34 |
5-(Piperidin-2-yl)- and 5-(homopiperidin-2-yl)-1,4-benzodiazepines: high-affinity, basic ligands for the cholecystokinin-B receptor. |
Merck Sharp & Dohme Research Laboratories |
| 9089338 |
29 |
Minor structural differences in Boc-CCK-4 derivatives dictate affinity and selectivity for CCK-A and CCK-B receptors. |
Abbott Laboratories |
| 8632410 |
33 |
Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for kappa-opioid receptors. |
Universitá |
| 8632408 |
24 |
Controlled modification of acidity in cholecystokinin B receptor antagonists: N-(1,4-benzodiazepin-3-yl)-N'-[3-(tetrazol-5-ylamino) phenyl]ureas. |
Neuroscience Research Centre |
| 8411002 |
67 |
Cholecystokinin peptidomimetics as selective CCK-B antagonists: design, synthesis, and in vitro and in vivo biochemical properties. |
University of Paris |
| 8145220 |
16 |
Second-generation benzodiazepine CCK-B antagonists. Development of subnanomolar analogs with selectivity and water solubility. |
Merck Research Laboratories |
| 7966138 |
55 |
5-Phenyl-3-ureidobenzazepin-2-ones as cholecystokinin-B receptor antagonists. |
Pfizer |
| 23489620 |
8 |
Synthesis and evaluation of cholecystokinin trimers: a multivalent approach to pancreatic cancer detection and treatment. |
Universit£ |
| 7837225 |
40 |
Ac-[3- and 4-alkylthioproline31]-CCK4 analogs: synthesis and implications for the CCK-B receptor-bound conformation. |
Washington University |
| 7692048 |
48 |
Synthesis and biological evaluation of cholecystokinin analogs in which the Asp-Phe-NH2 moiety has been replaced by a 3-amino-7-phenylheptanoic acid or a 3-amino-6-(phenyloxy)hexanoic acid. |
Ep Cnrs 51 |
| 18289861 |
36 |
Discovery of potent cholecystokinin-2 receptor antagonists: elucidation of key pharmacophore elements by X-ray crystallographic and NMR conformational analysis. |
Johnson & Johnson Pharmaceutical Research and Development |
| 18029172 |
23 |
Synthesis and solid-phase purification of anthranilic sulfonamides as CCK-2 ligands. |
Johnson & Johnson Pharmaceutical Research and Development |
| 11020274 |
142 |
Synthesis and SAR of new 5-phenyl-3-ureido-1,5-benzodiazepines as cholecystokinin-B receptor antagonists. |
Glaxo Wellcome Medicines Research Centre |
| 30395477 |
26 |
Receptor-Ligand Interaction Measured by Inductively Coupled Plasma Mass Spectrometry and Selenium Labeling. |
University of Montpellier |
| 3572963 |
11 |
Synthesis and biological activity of partially modified retro-inverso pseudopeptide derivatives of the C-terminal tetrapeptide of gastrin. |
TBA |
| 3336017 |
28 |
Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines. |
Merck Sharp & Dohme Research Laboratories |
| 2918498 |
18 |
Synthesis of gastrin antagonists, analogues of the C-terminal tetrapeptide of gastrin, by introduction of a beta-homo residue. |
Centre De Pharmacologie-Endocrinologie (Montpellier, France) |
| 2724293 |
28 |
Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors. |
University of Paris |
| 2153212 |
87 |
Cholecystokinin-A receptor ligands based on the kappa-opioid agonist tifluadom. |
Merck Sharp & Dohme Research Laboratories |
| 2016728 |
43 |
Quinazolinone cholecystokinin-B receptor ligands. |
Eli Lilly |
| 1992147 |
10 |
trans-3-n-propyl-L-proline is a highly favorable, conformationally restricted replacement for methionine in the C-terminal tetrapeptide of cholecystokinin. Stereoselective synthesis of 3-allyl- and 3-n-propyl-L-proline derivatives from 4-hydroxy-L-proline. |
Abbott Laboratories |
| 1766000 |
90 |
Cholecystokinin antagonists: (R)-tryptophan-based hybrid antagonists of high affinity and selectivity for CCK-A receptors. |
Abbott Laboratories |
| 1716682 |
64 |
Boc-CCK-4 derivatives containing side-chain ureas as potent and selective CCK-a receptor agonists. |
Abbott Laboratories |
| 1701834 |
20 |
Boc-Trp-Orn(Z)-Asp-NH2 and derivatives: a new family of CCK antagonists. |
University of Paris |
| 1501220 |
52 |
Synthesis and biological activity of CCK heptapeptide analogues. Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro, and appetite suppression in vivo. |
Abbott Laboratories |
| 1495013 |
24 |
N-methylated analogs of Ac[Nle28,31]CCK(26-33): synthesis, activity, and receptor selectivity. |
Hadassah-University Hospital |
| 26833890 |
18 |
Synthesis, Biological Evaluation, and Molecular Docking of 8-imino-2-oxo-2H,8H-pyrano[2,3-f]chromene Analogs: New Dual AChE Inhibitors as Potential Drugs for the Treatment of Alzheimer's Disease. |
Yogi Vemana University |
| 26469307 |
7 |
Phosphorylation of Capsaicinoid Derivatives Provides Highly Potent and Selective Inhibitors of the Transcription Factor STAT5b. |
University of Leipzig |
Search and Browse
